GU Cancers 2022 | HCRN-GU16-260: nivolumab and salvage nivolumab-ipilimumab in patients with advanced RCC

Michael Atkins, MD, Georgetown Lombardi Comprehensive Cancer Center, Washington DC, DC provides an overview of the Phase II HCRN-GU16-260 (NCT03117309) clinical trial investigating first-line therapy with nivolumab and salvage nivolumab-ipilimumab in patients with advanced renal cell carcinoma (RCC). The results were presented at the American Society of Clinical Oncology (ASCO) Genitourinary Cancers (GU) Symposium 2022 in San Francisco, including PD-L1 biomarker data. A total of 123 patients were enrolled. An overall response rate (ORR) of 34% was observed in patients receiving nivolumab monotherapy and patients in the favorable risk group achieved a response rate of 57%. This was in contrast to patients in the intermediate unfavorable risk group, which had a response rate of 25-30%. PD-L1 was demonstrated as a highly useful biomarker to predict PFS and response. This interview took place at the American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium 2022 in San Francisco, CA.